Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.90 CAD
Change Today -0.15 / -14.29%
Volume 28.2K
As of 2:11 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

covalon technologies ltd (COV) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/24/14 - C$2.98
52 Week Low
05/27/15 - C$0.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

covalon technologies ltd (COV) Related Businessweek News

No Related Businessweek News Found

covalon technologies ltd (COV) Details

Covalon Technologies Ltd. develops, licenses, and sells medical technologies. It operates in two segments, Advanced Wound Care and Specialized Medical Device Coatings. The company provides advanced wound care products comprising ColActive Plus Ag advanced wound care dressings; ColActive Transfer wound contact layers; CovaStat bio-active absorbable hemostatic sponges; and CovaSorb bio-active absorbent foam replacement dressings. It also offers IV Clear and SurgiClear antimicrobial silicone dressings. In addition, the company provides medical coatings that deliver infection control, therapeutic delivery, and lubricity, as well as CovaCoat medical coatings that offers photochemical process for covalently linking coating molecules to various medical device surfaces; and SilverCoat antimicrobial silicone foley catheters. Further, it offers process and manufacturing equipment validation assistance and on-site training services; and professional services, including feasibility studies, product formulation, prototype testing, validation, and manufacturing. The company sells its technologies and products to medical companies and distributors worldwide. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.

covalon technologies ltd (COV) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: C$325.0K
Co-Founder and Chief Science Officer
Total Annual Compensation: C$150.0K
Vice President of Operations
Total Annual Compensation: C$155.0K
Senior Director of Global Marketing
Total Annual Compensation: C$139.0K
Compensation as of Fiscal Year 2014.

covalon technologies ltd (COV) Key Developments

Covalon Technologies Ltd Introduces New Mediclear(Tm) Product Line Designed to Significantly Improve Patient Compliance with Efforts to Reduce Surgical Site Infections

Covalon Technologies Ltd. announced the introduction of its new MediClear(TM) product line designed to significantly improve patient compliance with efforts to reduce surgical site infections (SSI). Included in the MediClear(TM) line is Covalon's patent-pending MediClear(TM) PreOp - Antimicrobial Silicone Film Dressing, designed to replace other pre-operative skin preparation products, Covalon's next generation antimicrobial MediClear(TM) PostOp dressing and MediClear(TM) Scar. All three will be presented at AORN (Association of Perioperative Registered Nurses) Surgical Conference &Expo. Preoperative skin preparation products are a critical part of an infection control bundle, aimed at reducing surgical site infections (SSIs). A 2014 study suggested SSIs account for in excess of $3.5 billion in healthcare expenditures per year in the United States, not including the additional costs of hospitalization, post-discharge outpatient expenses, and long-term disability care and management. Covalon's MediClear(TM) line is intended to help reduce this financial burden on the U.S. healthcare system.

Covalon Technologies Ltd. Reports Earnings Results for the First Quarter Ended December 31, 2014

Covalon Technologies Ltd. reported earnings results for the first quarter ended December 31, 2014. For the quarter, the company’s revenue was $1,336,685. Net loss for the quarter was $229,820 or $0.02 per share.

Covalon Technologies Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2014

Covalon Technologies Ltd. reported earnings results for the fourth quarter and full year ended September 30, 2014. Revenue for the quarter was $1,206,159, and net loss for the quarter was $909,704. For the twelve months ended September 30, 2014, revenue was $9,061,329, an increase of $4,927,186 or 119%. Net income was $2,401,769 or $0.13 per share fully diluted which was significantly improved from the previous year's loss of $993,167 or $0.11 per share. The results also include increased revenue from sales of the company's advanced wound care products and specialized medical device coatings.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COV:CN C$0.90 CAD -0.15

COV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COV.
View Industry Companies

Industry Analysis


Industry Average

Valuation COV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVALON TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at